<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430963</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 60201-0520/1</org_study_id>
    <nct_id>NCT00430963</nct_id>
  </id_info>
  <brief_title>IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing
      proteins, i.e. free of proteins other than the active toxin. Injected into the muscle,
      IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used
      for aesthetic treatment of facial lines. This study investigated the efficacy and safety of
      IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo.
      The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days
      each.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's assessment according to the Facial Wrinkle Scale (FWS)</measure>
    <time_frame>Day 30</time_frame>
    <description>Responder: FWS score of 0 or 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's global assessment</measure>
    <time_frame>Day 30</time_frame>
    <description>Responder: subjects with a score of at least 2+.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's assessment according to FWS</measure>
    <time_frame>Day 7, 60, 90, and 120</time_frame>
    <description>Responder: FWS score of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment</measure>
    <time_frame>Day 7, 60, 90, and 120</time_frame>
    <description>Responder: subjects with a score of at least 2+.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) (20 Units)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA (Xeomin) (20 Units)</intervention_name>
    <arm_group_label>IncobotulinumtoxinA (Xeomin) (20 Units)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢Moderate to severe glabellar frown lines

        Exclusion Criteria:

          -  Previous insertion of permanent material in the glabellar area

          -  Neuromuscular function disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merz Pharmaceuticals GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>October 25, 2011</last_update_submitted>
  <last_update_submitted_qc>October 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

